Rawstorn Jonathan Charles, Ball Kylie, Oldenburg Brian, Chow Clara K, McNaughton Sarah A, Lamb Karen Elaine, Gao Lan, Moodie Marj, Amerena John, Nadurata Voltaire, Neil Christopher, Cameron Stuart, Maddison Ralph
Institute for Physical Activity and Nutrition, Deakin University, Geelong, Australia.
Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia.
JMIR Res Protoc. 2020 Jan 27;9(1):e15022. doi: 10.2196/15022.
Alternative evidence-based cardiac rehabilitation (CR) delivery models that overcome significant barriers to access and delivery are needed to address persistent low utilization. Models utilizing contemporary digital technologies could significantly improve reach and fidelity as complementary alternatives to traditional center-based programs.
The aim of this study is to compare the effects and costs of the innovative Smartphone Cardiac Rehabilitation, Assisted self-Management (SCRAM) intervention with usual care CR.
In this investigator-, assessor-, and statistician-blinded parallel 2-arm randomized controlled trial, 220 adults (18+ years) with coronary heart disease are being recruited from 3 hospitals in metropolitan and regional Victoria, Australia. Participants are randomized (1:1) to receive advice to engage with usual care CR or the SCRAM intervention. SCRAM is a 24-week dual-phase intervention that includes 12 weeks of real-time remote exercise supervision and coaching from exercise physiologists, which is followed by 12 weeks of data-driven nonreal-time remote coaching via telephone. Both intervention phases include evidence- and theory-based multifactorial behavior change support delivered via smartphone push notifications. Outcomes assessed at baseline, 12 weeks, and 24 weeks include maximal aerobic exercise capacity (primary outcome at 24 weeks), modifiable cardiovascular risk factors, exercise adherence, secondary prevention self-management behaviors, health-related quality of life, and adverse events. Economic and process evaluations will determine cost-effectiveness and participant perceptions of the treatment arms, respectively.
The trial was funded in November 2017 and received ethical approval in June 2018. Recruitment began in November 2018. As of September 2019, 54 participants have been randomized into the trial.
The innovative multiphase SCRAM intervention delivers real-time remote exercise supervision and evidence-based self-management behavioral support to participants, regardless of their geographic proximity to traditional center-based CR facilities. Our trial will provide unique and valuable information about effects of SCRAM on outcomes associated with cardiac and all-cause mortality, as well as acceptability and cost-effectiveness. These findings will be important to inform health care providers about the potential for innovative program delivery models, such as SCRAM, to be implemented at scale, as a complement to existing CR programs. The inclusion of a cohort comprising metropolitan-, regional-, and rural-dwelling participants will help to understand the role of this delivery model across health care contexts with diverse needs.
Australian New Zealand Clinical Trials Registry (ACTRN): 12618001458224; anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374508.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/15022.
为解决持续存在的低利用率问题,需要采用基于证据的替代性心脏康复(CR)交付模式,以克服获取和实施方面的重大障碍。利用当代数字技术的模式作为传统中心式项目的补充替代方案,可显著提高覆盖面和保真度。
本研究旨在比较创新的智能手机心脏康复辅助自我管理(SCRAM)干预与常规护理CR的效果和成本。
在这项研究者、评估者和统计学家均设盲的平行双臂随机对照试验中,从澳大利亚维多利亚州首府和地区的3家医院招募220名18岁及以上的冠心病成年人。参与者被随机(1:1)分配,接受参与常规护理CR的建议或SCRAM干预。SCRAM是一项为期24周的双阶段干预,包括由运动生理学家进行12周的实时远程运动监督和指导,随后是为期12周通过电话进行的数据驱动的非实时远程指导。两个干预阶段均包括通过智能手机推送通知提供基于证据和理论的多因素行为改变支持。在基线、12周和24周评估的结果包括最大有氧运动能力(24周时的主要结果)、可改变的心血管危险因素、运动依从性、二级预防自我管理行为、健康相关生活质量和不良事件。经济和过程评估将分别确定成本效益和参与者对治疗组的看法。
该试验于2017年11月获得资助,并于2018年6月获得伦理批准。2018年11月开始招募。截至2019年9月,已有54名参与者被随机纳入试验。
创新的多阶段SCRAM干预为参与者提供实时远程运动监督和基于证据的自我管理行为支持,无论他们与传统中心式CR设施的地理位置远近。我们的试验将提供关于SCRAM对与心脏和全因死亡率相关结果的影响、可接受性和成本效益的独特且有价值的信息。这些发现对于告知医疗保健提供者创新项目交付模式(如SCRAM)大规模实施的潜力非常重要,作为现有CR项目的补充。纳入包括来自首府、地区和农村的参与者队列将有助于了解这种交付模式在不同需求的医疗保健环境中的作用。
澳大利亚新西兰临床试验注册中心(ACTRN):12618001458224;anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374508。
国际注册报告标识符(IRRID):DERR1-10.2196/15022。